SRZN

Surrozen, Inc./DE

$22.81 -0.38 (-1.64%) At close · Jul 13

Market Cap

$264.83M

11,610,371

Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.

Revenue

$3.48M -67.4%

FY2025

Net Income

-$242.03M -280.8%

FY2025

Operating Margin

-1210.58% -970.9pp

FY2025

Diluted EPS

-$32.37 -49.4%

FY2025

Operating Cash Flow

-$30.24M -71.6%

FY2025

Chart any reported metric, KPI or segment over time — the full statement history lives here

Income Statement Balance Sheet Cash Flow All Metrics

Annual Quarterly

Line Item	3Y	5Y	10Y	TTM	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	-34.7%	—	—	$7.49M	$3.48M	$10.66M	$0	$12.5M	$0	—
Research & Development	-7.4%	+2.7%	—	$32.14M	$29.37M	$21.13M	$27.23M	$37.01M	$40.18M	$25.68M
General & Administrative	-6.5%	+17.9%	—	$18.36M	$16.2M	$15.06M	$15.8M	$19.83M	$14.21M	$7.12M
Depreciation & Amortization	-35.0%	-22.6%	—	—	$537K	$1.44M	$1.91M	$1.96M	$2.07M	$1.94M
Restructuring Charges	—	—	—	—	—	—	$2.75M	—	—	—
Total Operating Expenses	-7.1%	+6.8%	—	$50.49M	$45.57M	$36.19M	$45.78M	$56.84M	$54.39M	$32.81M
Operating Income	—	—	—	-$43M	-$42.09M	-$25.54M	-$45.78M	-$44.34M	-$54.39M	-$32.81M
Operating Margin	—	—	—	—	-1210.58%	-239.69%	—	-354.71%	—	—
EBITDA	—	—	—	—	-$41.56M	-$24.1M	-$43.87M	-$42.38M	-$52.33M	-$30.87M
Interest Income	+57.0%	+101.5%	—	$3.64M	$3.02M	$1.69M	$2.34M	$781K	$72K	$91K
Other Non-Operating Income	—	—	—	-$105.4M	-$26.31M	-$19.32M	$398K	$7.55M	-$329K	$0
Pretax Income	—	—	—	—	-$242.03M	-$63.56M	—	—	—	—
Income Tax	—	—	—	—	$0	$0	$0	$0	$0	$0
Net Income	—	—	—	-$342.56M	-$242.03M	-$63.56M	-$43.04M	-$36M	-$54.65M	-$32.72M
Net Margin	—	—	—	—	-6960.77%	-596.56%	—	-288.03%	—	—
Comprehensive Income	—	—	—	—	—	-$63.56M	-$42.8M	-$36.13M	-$54.77M	-$32.72M
EPS (Basic) USD/shares	—	—	—	—	-$32.37	-$21.67	-$21.33	-$15.56	-$33.15	—
EPS (Diluted) USD/shares	—	—	—	—	-$32.37	-$21.67	-$21.33	-$15.56	-$33.15	—
Shares Outstanding (Basic Avg) shares	+47.8%	-62.9%	—	—	7478	2933	2018	2314	1645.9333	1.06M
Shares Outstanding (Diluted Avg) shares	+47.8%	-62.9%	—	—	7478	2933	2018	2314	1645.9333	1.06M

Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.

Capital Returned to Shareholders

Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2021–FY2023: $2.61M in buybacks.

Price & Valuation

Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.

Valuation

EV/Revenue

—

Biotechnology median 8.34×

EV/EBIT

—

Biotechnology median 25.45×

P/E (TTM)

—

Biotechnology median 7.56×

Revenue Breakdown

Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.

Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.

By Product & Service (USD)

Component	2025-12-31	2024-12-31	2023-12-31
Research Service Revenue	$3,477,000	$655,000	$0
Collaboration and License Revenue	$0	$10,000,000	$0

Key facts CIK 1824893 CUSIP 86889P208 Visit website Investor relations